Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2011

01-04-2011 | Therapy In Practice

Erectile Dysfunction after Radical Prostatectomy

Treatment Options

Author: Dr Sidney Glina

Published in: Drugs & Aging | Issue 4/2011

Login to get access

Abstract

Erectile dysfunction is a common problem after radical prostatectomy, with almost all men experiencing this complication for at least a short period after such surgery. There is evidence that early use of phosphodiesterase type 5 inhibitors, intracavernous vasoactive drugs, intraurethral alprostadil or vacuum devices can improve the recovery of postoperative erectile function. The same therapeutic modalities can be used to treat erectile dysfunction after radical prostatectomy. Physicians must be active and counsel patients and partners to improve adherence to penile rehabilitation or erectile dysfunction treatment.
Literature
1.
2.
3.
4.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–84PubMedCrossRef
5.
Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172: 2227–31PubMedCrossRef
6.
7.
Bergman J, Gore JL, Penson DF, et al. Erectile aid use by men treated for localized prostate cancer. J Urol 2009; 182: 649–54PubMedCrossRef
8.
Dubbelman Y, Wildhagen M, Schroder F, et al. Orgasmic dysfunction after open radical prostatectomy: clinical correlates and prognostic factors. J Sex Med 2010; 7: 1216–23PubMedCrossRef
9.
Yu Ko WF, Degner LF, Hack TF, et al. Penile length shortening after radical prostatectomy: men’s responses. Eur J Oncol Nurs 2010; 14: 160–5PubMedCrossRef
10.
Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009; 6: 415–27PubMedCrossRef
11.
Mullerad M, Donohue JF, Li PS, et al. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med 2006; 3: 77–83PubMedCrossRef
12.
Walsh PC, Partin AW. Anatomical radical retropubic prostatectomy. In: Wein AJ, Kavoussi LR, Novick AC, et al., editors. Campbell-Walsh urology. 9th ed. Philadelphia (PA): Saunders Elsevier, 2007: 2956–78
13.
Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol. 2010; 20: 234–40PubMedCrossRef
14.
Lue TF, Zeineh SJ, Schmidt RA, et al. Neuroanatomy of penile erection: its relevance to iatrogenic impotence. J Urol 1984; 131: 273–80PubMed
15.
Hu J, Gu X, Stuart R, et al. Comparative effectiveness of minimally invasive vs. open radical prostatectomy. J Am Med Assoc 2009; 302: 1557–64CrossRef
16.
Penson DF, Latini DM, Lubeck DP, et al. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction to other causes? Results from the ExCEED data base. J Urol 2003; 169: 1458–61PubMedCrossRef
17.
Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–60PubMedCrossRef
18.
McCammon KA, Kolm P, Main B, et al. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999; 54: 509–16PubMedCrossRef
19.
Nelson CJ, Deveci S, Stasi J, et al. Sexual bother following radical prostatectomy. J Sex Med 2010; 7: 129–35PubMedCrossRef
20.
Kornblith AB, Herr HW, Ofman US, et al. Quality of life of patients with prostate cancer and their spouses: the value of a data base in clinical care. Cancer 1994; 73: 2791–802PubMedCrossRef
21.
Kava BR. Advances in the management of post-radical prostatectomy erectile dysfunction: treatment strategies when PDE-5 inhibitors don’t work. Rev Urol 2005; 7: S39PubMed
22.
Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806–15PubMedCrossRef
23.
Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005; 174: 230–9PubMedCrossRef
24.
Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5PubMedCrossRef
25.
Hatzimouratidis K, Burnett AL, Hatzichristou D, et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55: 334–47PubMedCrossRef
26.
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005; 2: 658–67PubMedCrossRef
27.
Ohebshalom M, Parker M, Waters B, et al. Erectile haemodynamic status after radical prostatectomy correlates with erectile functional outcome. BJU Int 2008; 102: 592–6PubMedCrossRef
28.
Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278–83PubMedCrossRef
29.
Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777–83PubMedCrossRef
30.
Montorsi F, Nathan HP, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036–41PubMedCrossRef
31.
Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008; 5: 946–53PubMedCrossRef
32.
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010; 7: 1928–36PubMedCrossRef
33.
Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008 Nov; 5(11): 2672–80PubMedCrossRef
34.
Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200–6PubMedCrossRef
35.
Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety ofonce-a-day dosingoftadalafil 5 mgand 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351–9PubMedCrossRef
36.
Masterson TA, Serio AM, Mulhall JP, et al. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. BJU Int 2008; 101: 1217–22PubMedCrossRef
37.
Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008; 18: 613–20PubMedCrossRef
38.
Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007; 4: 538–43PubMedCrossRef
39.
Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408–10PubMedCrossRef
40.
Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2: 532–40PubMedCrossRef
41.
Mulhall JP, Bella AJ, Briganti A, et al. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7: 1687–98PubMedCrossRef
42.
Lee CH, Shin JH, Ahn GJ, et al. Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection. J Sex Med 2010; 7: 2564–71PubMed
43.
Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20: 479–86PubMedCrossRef
44.
Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004; 171: 771–4PubMedCrossRef
45.
Bannowsky A, Schulze H, van der Horst C, et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101: 1279–83PubMedCrossRef
46.
Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54: 924–31PubMedCrossRef
47.
Mulhall JP. Does on-demand vardenafil improve erectile function recovery after radical prostatectomy? Nat Clin Pract Urol. 2009; 6: 14–5PubMedCrossRef
48.
Deho F, Gallina A, Salonia A, et al. Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors. Curr Pharm Des 2009; 15: 3496–501PubMedCrossRef
49.
Mulhall JP, Parker M, Waters BW, et al. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105: 37–41PubMedCrossRef
50.
User HM, Hairston JH, Zelner DJ, et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003; 169: 1175–9PubMedCrossRef
51.
Bosshardt RJ, Farwerk R, Sikora R, et al. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. BJU 1995; 75: 786–91PubMedCrossRef
52.
Raina R, Agarwal A, Ausmundson S, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77–81PubMedCrossRef
53.
Dalkin BL, Christopher BA. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int J Impot Res. 2007; 19: 501–4PubMedCrossRef
54.
Kohler TS, Pedro R, Hendlin K, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007; 100: 858–62PubMedCrossRef
55.
Raina R, Pahlajani G, Agarwal A, et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int 2010; 106(11): 1719–22PubMedCrossRef
56.
Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325–8PubMedCrossRef
57.
Raina R, Agarwal A, Zaramo CE, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005; 17: 86–90PubMedCrossRef
58.
McCullough AR, Hellstrom WG, Wang R, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183: 2451–6PubMedCrossRef
59.
Teloken P, Mesquita G, Montorsi F, et al. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009; 6: 2032–8PubMedCrossRef
60.
61.
Sidi AA, Reddy PK, Chen KK. Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol. 1988; 140: 293–4PubMed
62.
Gheorghiu S, Godschalk M, Gentili A, et al. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction. J Urol 1996; 156: 80–1PubMedCrossRef
63.
Alexandre B, Lemaire A, Desvaux P, et al. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007; 4: 426–31PubMedCrossRef
64.
Dennis RL, McDougal WS. Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol. 1988; 139: 775–6PubMed
65.
Baniel J, Israilov S, Segenreich E, et al. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int 2001; 88: 58–62PubMedCrossRef
66.
Raina R, Lakin MM, Thukral M, et al. Long-term efficacy and compliance of intracorporal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318–22PubMedCrossRef
67.
Claro JA, Aboim JE, Maríngolo M, et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 2001 5; 119: 135–7
68.
Albaugh J, Ferrans CE. Patient-reported pain with initial intracavernosal injection. J Sex Med. 2009; 6: 513–9PubMedCrossRef
69.
Vrijhof HJ, Delaere KP. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence oforganic or mixed aetiology. Br J Urol. 1994; 74: 102–5PubMedCrossRef
70.
Turner LA, Althof SE, Levine SB, et al. Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological, and marital functioning. J Urol 1990; 144: 79–82PubMed
71.
McCullough AR. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin North Am. 2001; 28: 613–27PubMedCrossRef
Metadata
Title
Erectile Dysfunction after Radical Prostatectomy
Treatment Options
Author
Dr Sidney Glina
Publication date
01-04-2011
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2011
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11588290-000000000-00000

Other articles of this Issue 4/2011

Drugs & Aging 4/2011 Go to the issue

Current Opinion

Understanding Patient Compliance and Persistence with Osteoporosis Therapy

Original Research Article

Polypharmacy and Nutritional Status in Older Adults

Original Research Article

Quality Indicators for In-Hospital Pharmaceutical Care of Dutch Elderly Patients

Original Research Article

Effects of Medication Review on Drug-Related Problems in Patients Using Automated Drug-Dispensing Systems

Review Article

Effects of Common Topical Antiglaucoma Medications on the Ocular Surface, Eyelids and Periorbital Tissue

Adis Spotlight

Spotlight on Histamine Dihydrochloride in Acute Myeloid Leukaemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits